Skip to main content
Back to

Jorge Santos da Silva

Partner, Zurich
Counsels biopharmaceutical, medical device, and diagnostic companies in mature and emerging markets on strategy, operating models, and organization

About Jorge

Jorge is a leader in our Pharmaceutical & Medical Products Practice. He advises biopharma, medical device, and diagnostic companies on corporate and business-unit strategy, commercial operating models, R&D, organizational design, M&A, joint ventures, and marketing and sales.

In the past few years, Jorge has:

  • worked with several companies to define strategies for biopharma products at a global level and in specific emerging markets, including implementation and business plans.
  • helped a top generics company to design its operating models in emerging markets, including country-by-country scenario development, portfolio management, and M&A screening.
  • supported the formation of biopharma joint ventures and public–private partnerships in emerging markets.
  • developed growth options for a medical diagnostics company, including local technology platforms.
  • led our support for major integrations and commercial transformations across geographic regions and product ranges.
  • performed due diligence on biopharma companies, with emphasis on the biotech process and portfolio.

Jorge has published a number of articles on pharma R&D, biosimilars, and other industry topics, as well as several scientific papers written during his earlier research career. With an academic background in molecular biology and neuroscience, he holds a BSc from the University of Glasgow, an MSc from EMBL in Heidelbert, and a PhD from the University of Turin. He completed his post-doctoral studies at the Cold Spring Harbor Laboratory in New York.

Published work

Understanding the opportunity in Japan’s biosimilar market,” McKinsey & Company, September 2019

“Biotech in Europe: A strong foundation for growth and innovation,” McKinsey & Company, August 2019

What’s next for biosimilars in emerging markets?,” McKinsey & Company, April 2019

Five things to know about biosimilars right now,” McKinsey & Company, July 2018

Africa: A continent of opportunity for pharma and patients,” McKinsey & Company, June 2015

“The rise of biosimilars: Navigating the distinctive path to market,” From Science to Operations: Questions, choices, and strategies for success in biopharma (PDF–790 KB), McKinsey & Company, 2014

Biosimilars seven years on: Where are we and what's next?,” McKinsey & Company, February 2013 (PDF–657 KB)

“Public–private partnerships: An untapped strategic lever,” Unlocking pharma growth (PDF–2.91 MB), McKinsey & Company, 2012

Closing the R&D gap in African health care,” Evolution or revolution?, McKinsey & Company, 2012

Past experience

Cold Spring Harbor Laboratory, New York


University of Turin
PhD, neuroscience

European Molecular Biology Laboratory, Heidelbert
MSc, neurobiology

University of Glasgow
BSc, molecular biology